TargetMol

NG,NG-dimethyl-L-Arginine dihydrochloride

Product Code:
 
TAR-T21546
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T21546-10mg10mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21546-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21546-5mg5mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21546-1mL1 mL * 10 mM (in DMSO)£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
NG,NG-dimethyl-L-Arginine dihydrochloride is an endogenous nitric oxide synthase inhibitor. Nitric oxide (NO) that is synthesised from L-arginine contributes to the regulation of blood pressure and to host defence[1].
CAS:
220805-22-1
Formula:
C8H20Cl2N4O2
Molecular Weight:
275.18
Pathway:
Immunology/Inflammation
Purity:
0.9918
SMILES:
N[C@@H](CCCNC(N(C)C)=N)C(O)=O.[H]Cl.[H]Cl
Target:
NO Synthase

References

1. Wu M, et al. Renal asymmetric dimethylarginine inhibits fibrosis. FEBS Open Bio. 2020 Oct;10(10):2003-2009. doi: 10.1002/2211-5463.12949. Epub 2020 Aug 30. 2. Wu M, et al. Reduced asymmetric dimethylarginine accumulation through inhibition of the type I protein arginine methyltransferases promotes renal fibrosis in obstructed kidneys. FASEB J. 2019 Jun;33(6):6948-6956.